معلومات مباشر
Anthropic Prepares for IPO by Holding Meetings with Potential Investors
G7 and European Union Call for Immediate Ceasefire in Sudan and Protection of Civilians in Al-Obeid
Saudi Export Bank signs credit line agreement with Iraqi Al-Mansour Bank
Saudi Football Federation Launches Competitions for Under-5, Under-7, and Under-9 Age Groups
Aramco awards Halliburton multi-year contract for unconventional gas development
المصدر: معلومات مباشر
21 Hrsجاهز للتشغيل
جاهز للتشغيل
Shares of Silkwayt decreased by 19% after the postponement of the launch of their new breast cancer treatment, despite the U.S. Food and Drug Administration's approval of the drug "Gidetoliseeb," marketed as "Riftrebic," for a specific type of advanced breast cancer. The product was initially expected to be launched in the third quarter, but the company delayed the release to ensure sufficient quantities are available, without revealing the price, which is anticipated to be higher than current treatments. The drug has demonstrated significant clinical results, reducing the risk of disease progression or death by 76%, although some patients experience side effects such as severe mouth inflammation. Sales of the drug are expected to reach $36 million in 2026, with a monthly cost of approximately $28,000.
تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي
comments.heading